公开(公告)号：US20140081012A1

公开(公告)日：2014-03-20

申请号：US13985491

申请日：2012-02-15

Applicant: Joseph M. DeSimone ,  Mary Napier ,  Jin Wang ,  Jing Xu ,  Shaomin Tian ,  Stuart Dunn

Inventor： Joseph M. DeSimone ,  Mary Napier ,  Jin Wang ,  Jing Xu ,  Shaomin Tian ,  Stuart Dunn

IPC: C07D207/46 ,  C12N15/113

CPC classification number: C07D207/46 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/08 ,  A61K47/54 ,  A61K47/543 ,  A61K47/60 ,  A61K47/6929 ,  C07D233/90 ,  C07D403/12 ,  C12N15/113

Abstract: Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain an agent having a reversible disulfide linker and to vehicles that are covalently linked to the agent containing a reversible disulfide linker. The modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting while the reversibility of the linker can leave the agent to which it is attached free from residual chemical groups after being reduced.

Abstract translation: 描述了含有可逆二硫键的制药，化学和生物制剂。 这些试剂也可以共价结合或包含在递送载体中，以将试剂递送到期望的靶或区域。 还描述了含有具有可逆二硫键接头的试剂和与含有可逆二硫键接头的试剂共价连接的载体的载体。 本文所述的修饰可以改变试剂和载体的性质，从而提供所需的溶解性，稳定性，疏水性和靶向性，而连接物的可逆性可以在其被还原后离开残留化学基团的试剂离开。

公开(公告)号：US08642546B2

公开(公告)日：2014-02-04

申请号：US13327504

申请日：2011-12-15

Applicant: Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/50 ,  A61K39/395 ,  C07K16/00

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant fusion polypeptides comprising mutations at positions 98, 171, 179, 180 or 181, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract translation: 本发明提供编码FGF21突变融合多肽的核酸分子，其包含位置98,171,179,180或181，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的突变，以及使用此类核酸，多肽或 药物组合物。

公开(公告)号：US20130224198A1

公开(公告)日：2013-08-29

申请号：US13872790

申请日：2013-04-29

Applicant: Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

Inventor： Haitao WANG ,  Yong DU ,  Rui ZHANG ,  Jing XU ,  Longbin LIU

IPC: A61K47/48 ,  C07K14/505

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic bioactivity compared to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human IgG1, which Fc fragment includes the hinge region, CH2 and CH3 domains. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen risk of an immunogenic response when administered. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6.

Abstract translation: 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白具有延长的体内半衰期。 在一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人IgG1的Fc片段的肽序列，所述Fc片段包括铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头，并且当施用时降低免疫原性反应的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。

公开(公告)号：US08458550B2

公开(公告)日：2013-06-04

申请号：US12920658

申请日：2009-02-24

Applicant: Haifeng Wang ,  Ting Zhou ,  Jing Xu

Inventor： Haifeng Wang ,  Ting Zhou ,  Jing Xu

IPC: H04L1/18

CPC classification number: H04W24/00 ,  H04B7/2606 ,  H04L1/0045 ,  H04L1/1607 ,  H04L1/1812 ,  H04L2001/0097 ,  H04W16/26 ,  H04W28/04 ,  H04W84/047

Abstract: Various example embodiments are disclosed herein. In an example embodiment, a method of transmitting data via a wireless transmission path that may include a user equipment as a first end point, a base station as second end point, and at least one relay station as an intermediate point(s). The method may include receiving a data transmission from a prior point in the transmission path. Substantially simultaneously: forwarding the received data to the next point in the transmission path, and determining if the received data is corrupt. Transmitting a transmission message to the next point in the transmission path indicating whether or not the received data was corrupt. And, if the data is not corrupt, transmitting a receipt message to the prior point indicating that the data was uncorrupt when received.

Abstract translation: 本文公开了各种示例性实施例。 在一个示例实施例中，一种经由无线传输路径发送数据的方法，该无线传输路径可以包括作为第一终点的用户设备，作为第二终点的基站和作为中间点的至少一个中继站。 该方法可以包括从传输路径中的先前点接收数据传输。 基本同时：将接收的数据转发到传输路径中的下一个点，并确定接收的数据是否已损坏。 将传输消息发送到传输路径中的下一个点，指示接收到的数据是否已损坏。 而且，如果数据没有被破坏，则将接收消息发送到先前点，表示数据在接收时未被破坏。

公开(公告)号：US08437637B2

公开(公告)日：2013-05-07

申请号：US12955730

申请日：2010-11-29

Applicant: Jing Xu ,  Lian-kuan Chen ,  Chun-kit Chan

Inventor： Jing Xu ,  Lian-kuan Chen ,  Chun-kit Chan

IPC: H04J14/00

CPC classification number: H04B10/272 ,  H04J14/0239 ,  H04J14/0246 ,  H04J14/025 ,  H04J14/0282 ,  H04J2014/0253

Abstract: Disclosed are a system and a method for controlling multicast data. The system may comprise: a plurality of transceivers, each of which comprises a laser configured to generate an optical carrier, the generated optical carrier being modulated by electrical downstream p-t-p data so as to generate optical downstream p-t-p IRZ signal; a PM configured to modulate the generated optical downstream p-t-p IRZ signal by electrical multicast data so as to generate orthogonally modulated signal; and a DI configured to demodulate the orthogonally modulated data and has a frequency response peak or dip in response to the demodulating, wherein an offset of a laser center wavelength of the laser from the frequency response peak or dip is adjustable so as to selectively enable or disable the multicast data.

Abstract translation: 公开了一种用于控制多播数据的系统和方法。 该系统可以包括：多个收发器，每个收发器包括被配置为产生光载波的激光器，所产生的光载波被电气下游p-t-p数据调制，以产生光下游p-t-p IRZ信号; 配置为通过电组播数据调制所生成的光下行p-t-p IRZ信号的PM，以产生正交调制信号; 以及配置为对所述正交调制数据进行解调并且响应于所述解调而具有频率响应峰值或倾角的DI，其中所述激光器的激光中心波长与所述频率响应峰值或倾角的偏移是可调节的，以便选择性地启用或 禁用组播数据。

公开(公告)号：US08431132B2

公开(公告)日：2013-04-30

申请号：US12555743

申请日：2009-09-08

Applicant: Haitao Wang ,  Du Yong ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

Inventor： Haitao Wang ,  Du Yong ,  Rui Zhang ,  Jing Xu ,  Longbin Liu

IPC: A61K39/00 ,  C07K1/00 ,  C07K16/00

CPC classification number: C07K14/505 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/6811 ,  C07K2317/53 ,  C07K2319/30

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

Abstract translation: 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比，融合蛋白在体内具有延长的半衰期。 在本发明的一个实施方案中，蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比，融合蛋白也表现出增强的红细胞生物活性。 在一个实施方案中，融合蛋白包含人促红细胞生成素（EPO）分子的完整肽序列和人免疫球蛋白IgG1的Fc片段的肽序列。 融合蛋白中的Fc片段包括人免疫球蛋白IgG1的铰链区，CH2和CH3结构域。 EPO分子可以直接连接到Fc片段，以避免外来的肽接头并且当在体内施用时减轻免疫原性应答的风险。 在一个实施方案中，铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。本发明还涉及编码融合蛋白和转染细胞系的核酸和氨基酸序列以及用于产生融合蛋白的方法。 本发明还包括包含融合蛋白的药物组合物和使用融合蛋白和/或药物组合物的方法，例如刺激需要治疗的受试者的红细胞生成。

公开(公告)号：US08410051B2

公开(公告)日：2013-04-02

申请号：US13196544

申请日：2011-08-02

Applicant: Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/50 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12N15/63

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

公开(公告)号：US08361963B2

公开(公告)日：2013-01-29

申请号：US13328028

申请日：2011-12-16

Applicant: Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/50

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

公开(公告)号：US08265303B2

公开(公告)日：2012-09-11

申请号：US12401905

申请日：2009-03-11

Applicant: Hongbo Zhang ,  Vincent Fong ,  Jing Xu ,  Yuling Khang

Inventor： Hongbo Zhang ,  Vincent Fong ,  Jing Xu ,  Yuling Khang

IPC: H04B1/00

CPC classification number: H03F1/305 ,  H03F3/217

Abstract: In one embodiment the present invention includes a method for starting up a class D amplifier. The method comprises increasing, gating, and driving. The increasing includes increasing a duty cycle of a pulse train from a first duty cycle to a second duty cycle. The gating includes gating a signal based on the increasing of the duty cycle. The gating results in a gated signal. The driving includes driving an output signal from the gated signal to charge an output capacitor. The output capacitor is coupled to a speaker. The increasing of the duty cycle contributes to the charging of the output capacitor such that switching sounds detectable by the human ear are reduced.

Abstract translation: 在一个实施例中，本发明包括用于启动D类放大器的方法。 该方法包括增加，门控和驾驶。 增加包括将脉冲串从第一占空比增加到第二占空比的占空比。 门控包括基于占空比的增加来门控信号。 门控产生门控信号。 驱动包括驱动来自门控信号的输出信号以对输出电容器充电。 输出电容耦合到扬声器。 占空比的增加有助于输出电容器的充电，使得由人耳可检测的开关声音减小。

公开(公告)号：US20120170189A1

公开(公告)日：2012-07-05

申请号：US13298301

申请日：2011-11-17

Applicant: WU-GUO LI ,  BING-JING XU ,  CHUN-CHE YEN ,  YANG-GEN LIU ,  YU-TAO CHEN ,  TE-SHENG JAN

Inventor： WU-GUO LI ,  BING-JING XU ,  CHUN-CHE YEN ,  YANG-GEN LIU ,  YU-TAO CHEN ,  TE-SHENG JAN

IPC: H05K7/00

CPC classification number: F16M13/005 ,  F16M11/22 ,  F16M2200/08 ,  G06F1/1626 ,  G06F1/166

Abstract: An exemplary portable electronic device includes a housing defining an opening, an internal fixing element including a pair of protruding blocks and defining a groove in communication with the opening, and a support mechanism. The groove defines a stepped structure and includes a larger groove portion, and a smaller groove portion communicating with the larger groove portion. The support mechanism is slidably receivable in the housing, and includes a support and a slider defining a recess. The slider includes a connection portion received in the recess and a head set atop the connection portion. The connection portion abuts the pair of the protruding blocks when the slider is in a retracted position. The head is received in the larger groove portion and slidably resting on a step formed between the larger and smaller groove portions. The support includes a body and a board connected to one end of the body.

Abstract translation: 示例性便携式电子设备包括限定开口的壳体，包括一对突出块的内部固定元件和限定与开口连通的槽以及支撑机构。 所述槽限定了阶梯状结构，并且包括较大的槽部，以及与较大的槽部连通的较小的槽部。 支撑机构可滑动地容纳在壳体中，并且包括支撑件和限定凹部的滑块。 滑块包括容纳在凹部中的连接部分和设置在连接部分顶部的头部。 当滑块处于缩回位置时，连接部分邻接该对突出块。 头部被容纳在较大的凹槽部分中并可滑动地搁置在形成在较大和较小的凹槽部分之间的台阶上。 支撑件包括连接到身体的一端的主体和板。